Cover Image

The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker

Abstract Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy‐eight patients were included in the study, 50 Stroke with AF (AF‐S), and 28...

Full description

Saved in:

Bibliographic Details
Main Authors:	Matthew J. Lawrence (Author), Vanessa Evans (Author), Janet Whitley (Author), Suresh Pillai (Author), Phylip R. Williams (Author), James Coulson (Author), Manju Krishnan (Author), Peter Slade (Author), Kieron Power (Author), Roger H.K. Morris (Author), Phillip A. Evans (Author)
Format:	Book
Published:	Wiley, 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015)

APIXABAN IN THE TREATMENT OF ATRIAL FIBRILLATION: RANDOMIZED TRIALS AND EVERYDAY CLINICAL PRACTICE
by: O. O. Shakhmatova, et al.
Published: (2017)

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol
by: Josep Comin Colet, et al.
Published: (2023)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017)

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2015)

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2015)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
by: Frost C, et al.
Published: (2014)

PHARMACODYNAMICS OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ACUTE PERIOD OF ISCHEMIC STROKE
by: V. I. Petrov, et al.
Published: (2021)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
by: Maxim Grymonprez, et al.
Published: (2023)

Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke
by: Kryukov AV, et al.
Published: (2018)

APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN
by: O. D. Ostroumova, et al.
Published: (2018)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
by: Frost C, et al.
Published: (2018)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
by: Frost C, et al.
Published: (2018)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
by: Cui Y, et al.
Published: (2013)

Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation
by: A. S. Kolbin, et al.
Published: (2023)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
by: Hallinen T, et al.
Published: (2021)

Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
by: L. V. Fedina, et al.
Published: (2023)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
by: Cui Y, et al.
Published: (2014)

An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation
by: Mariana Floria, et al.
Published: (2024)

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
by: Samira J. Merali, et al.
Published: (2023)

Atrial Fibrillation Mechanisms and Treatment
Published: (2013)

HYPERTHYROIDISM AND ATRIAL FIBRILLATION
by: I. M. Marusenko, et al.
Published: (2017)

Screening for atrial fibrillation
by: Zhenisgul Tlegenova, et al.
Published: (2018)

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban
by: Mohamed F. Zaky, et al.
Published: (2023)

Drug-Induced Atrial Fibrillation / Atrial Flutter
by: O. D Ostroumova, et al.
Published: (2022)

According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention
by: Company Pfizer
Published: (2019)

According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention
by: Company Pfizer
Published: (2019)

Antithrombotic therapy in chronic liver disease: to clot or not to clot
by: Peter Calvert, et al.
Published: (2021)

Atrial Fibrillation Basic Research and Clinical Applications
Published: (2012)

Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis
by: l. V. Fedina, et al.
Published: (2024)

Atrial Fibrillation Diagnosis and Management in the 21st Century
Published: (2022)

Stroke, Dementia and Atrial Fibrillation
Published: (2020)

Epidemiology and Treatment of Atrial Fibrillation
Published: (2020)

New Perspective in Atrial Fibrillation
Published: (2021)

Atrial Fibrillation Secondary to Dehydration
by: Kriti Bhatia
Published: (2014)

GENETIC PREDICTORS OF ATRIAL FIBRILLATION
by: A. V. Kuskaeva, et al.
Published: (2016)

Atrial Fibrillation in Hypertrophic Cardiomyopathy
by: G. A. Ignatenko, et al.
Published: (2021)

Iron deficiency and atrial fibrillation
by: Metin Okşul, et al.
Published: (2018)